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Background: In congestive heart failure the balance between cell death and cell survival in cardiomyocytes is
compromised. Sirtuin 1 (Sirt1) activates cell survival machinery and has been shown to be protective against
ischemia/reperfusion injury in murine heart. The role of Sirt1 in heart failure, especially in human hearts is not clear.
Results: The expression of Sirt1 and other (associated) downstream molecules in human cardiomyocytes from
patients with advanced heart failure was examined. Sirt1 was down-regulated (54.92% ± 7.80% in advanced heart
failure samples compared with healthy control cardiomyocytes). The modulation of molecules involved in
cardiomyocyte survival and death in advanced heart failure were also examined. The expression of Mn-superoxide
dismutase and thioredoxin1, as well as an antiapoptotic molecule, Bcl-xL, were all significantly reduced in advanced
heart failure cardiomyoctes (0.71 ± 0.02-fold, 0.61 ± 0.05-fold, and 0.53 ± 0.08-fold vs. control, respectively);
whereas the expression of proapoptotic molecule Bax was significantly increased (1.62 ± 0.18-fold vs. control).
Increased TUNEL-positive number of cardiomyocytes and oxidative stress, confirmed by 8-hydorxydeoxyguanosine
staining, were associated with advanced heart failure. The AMPK-Nampt-Sirt1 axis also showed inhibition in advanced
heart failure in addition to severely impaired AMPK activation. Increased p53 (acetyl form) and decreased FoxO1
translocation in the nucleus may be the mechanism of down-regulation of antioxidants and up-regulation of
proapoptotic molecules due to low expression of Sirt1.
Conclusion: In advanced heart failure, low Sirt1 expression, like aging change may be a significant contributing
factor in the downregulation of antioxidants and upregulation of proapoptotic molecules through the p53, FoxO1,
and oxidative stress pathways.
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Despite recent progress, congestive heart failure remains
a major cause of death in Western countries. The preva-
lence of congestive heart failure (CHF) increases with age
[1]. Due to the increased average life expectancy over the
past decade and the increased proportion of aged individ-
uals, it is expected that CHF diagnoses will increase
steeply in the near future.
There has been great progress towards understanding
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unless otherwise stated.evidence suggests that the progression of heart failure is
determined by the imbalance between cell death promo-
tion and cell survival/protective mechanisms [2]. In CHF
or in an aging heart a predominant factor is the role of cell
death [3].
Sirtuin 1 is a member of the Sirtuin family of class III
histone deacetylases. Sirt1 is involved in gene silencing,
longevity, cellular senescence, cell differentiation, and cell
survival [4,5]. It has been shown that Sirt1 activity en-
hances the lifespan of several organisms, including yeast,
C. elegans, and metazoan [6-8]. The protein expression of
Sirt1 in the heart has been demonstrated to be the highest
in the embryo with progressive reductions associated with
aging [9]. These observations imply that Sirt1 may play an
important role in the aging process, and with cardiomyo-
cyte death and survival.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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changes associated with aging in cardiomyocytes using a
transgenic mouse as the model [10]. We have also found
that Sirt1 expression was significantly reduced in hearts
subjected to ischemic/reperfusion. Preconditioning before
ischemic/reperfusion increased Sirt1 expression, and was
associated with the upregulation of antioxidants and
downregulation of proapoptotic molecules, partly through
the activation of FoxO1 and reduced oxidative stress [11].
In vitro, endogenous Sirt1 has been found to play an
essential role in mediating cardiomyocyte survival: over-
expression of Sirt1 has provided protective effects for cardi-
omyocytes from apoptosis, whereas downregulation of Sirt1
may be associated with apoptotic cell death [12]. However,
expression of Sirt1 in advanced heart failure models is not
clear and remains controversial. Pillai et al. showed that
Sirt1 is down-regulated in heart failure from human sam-
ples [13]: however, Alcendor et al. showed that Sirt1 is
up-regulated after 4 weeks of pressure overload in mice, a
condition used to represent the stage of heart failure [10].
In CHF, the ventricle or atrium wall tension is increased
which subjects the cardiomyocytes to higher pressure and
relative ischemia compared with normal healthy control
hearts. It is implied that the molecular change following
ischemia or ischemic/reperfusion in the mouse heart could
be applied to the condition of CHF in human beings.
Therefore, the goal of this study was to determine the
expression of Sirt1 and the associated molecules involved
in cell death or survival in a human model.
Methods
Collection of cardiac samples
This study was performed according to the guidelines of
the Declaration of Helsinki. All procedures involved
human tissue were approved by the institutional review
boards of the Taipei Veterans General Hospital. Consent
was obtained from patients or their families before tissue
procurement. Myocardial samples over the posterior wall
of the left atrium were collected from donors while being
prepared for transplantation. Myocardial samples near the
mitral annulus were obtained from patients at the time of
therapeutic transplantation. Samples for biochemical ana-
lyses were stored at −80°C immediately after procurement.
Selected samples for immunostaining were fixed in 4%
paraformaldehyde in phosphate-buffered saline (pH 7.4),
paraffin-embedded, and sectioned. C57BL/6JNarl mice were
obtained from National Laboratory Animal Center of
Taiwan, and the investigation conformed with the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health.
Cell cultures and materials
H9c2 cells (rat cardiomyoblasts), obtained from ATCC
(Manassas, VA), and were cultured in DMEM supplementedwith 10% fetal bovine serum under an atmosphere of 95%
air/5% CO2 at 37°C. Compound C (Merck) was added to
the medium for the times and at the doses indicated. The
antibodies used included Sirt1, 8-OHdG goat polyclonal
(Millipore), MnSOD (Upstate Biotechnology), Sirt1 rabbit
polyclonal, Trx1, Troponin C mouse monoclonal (Santa
Cruz), p53, Acetyl-p53 (Lys379), AMPKα and phospho-
AMPKα(Thr172) (Cell Signaling), Nampt (Bethyl), Bcl-xL
(Pharmingen), Bax (Abcam), FoxO1 rabbit monoclonal
(Epitomics), and tubulin (Sigma).
Immunoblot analysis
Heart samples were placed in lysis buffer (50 mmol/L
Tris–HCl pH 7.4, 0.1% SDS, 1% NP40, 0.15 mol/L NaCl,
0.25% Na-deoxycholate, and 1 mmol/L EDTA supple-
mented with protease inhibitors). Densitometric analysis
was performed using Scion Image software (Scion).
Immunohistochemistry and immunofluorescence
The paraffin-embedded heart specimens, sectioned at 4-
μm thickness, were deparaffinized and rehydrated in PBS.
Pretreatments included microwave antigen retrieval in a
10 mM citrate buffer for 20 min. Immunohistochemical
staining was performed using an immunocruz staining
system (streptavidin-biotin peroxidase method), and sec-
tions were counterstained with hematoxylin. Immunofluor-
escence analysis was achieved using primary antibodies of
Sirt1 (Santa Cruz), FoxO1 (Epitomics), acetyl-p53 (Cell
Signaling), and/or Troponin C (Santa Cruz) after a blocking
step with 3% BSA for 30 minutes. DyLight ™488-conjugated
and/or ™594-conjugated affinipure IgG (Thermo Fisher
Scientific) were used for secondary antibodies.
Evaluation of apoptosis in tissue sections
Deoxyribonucleic acid (DNA) fragmentation was de-
tected in situ using TUNEL Briefly, deparaffinized tissue
sections were incubated with proteinase K, and DNA
fragments were labeled with fluorescein-conjugated dUTP
using TdT (Roche Molecular Biochemicals). Myocyte was
identified by Troponin C antibody. Cell nuclei were coun-
terstained with DAPI (blue).
Statistics
All values were expressed as mean ± SEM. Statistical ana-
lyses between groups were done using a one-way ANOVA,
and when F values were significant at a 95% confidence
limit, differences among group means were evaluated using
Fisher’s project least significant difference post-test proced-
ure for group data. A P value less than 0.05 was considered
significant.
Results
Totally, the cardiac tissue samples were harvested from
10 donors (eight males, aged 37.5 ± 3.9 years) and 10
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40.1 ± 3.7 years, P = 0.637). The cardiothoracic ratio of
recipients was 67.65 ± 1.06%, measured by posteroan-
terior film of chest x ray.
Sirt1 is down-regulated in advanced heart failure of
human beings
The expression of Sirt1 decreased to 54.92 ± 7.80% com-
pared to donor hearts (Figure 1A). In advanced heart
failure, atrial myocyte showed some hypertrophy and
disarragement as expected (Hematoxylin-eosin staining
in Figure 1B). Sirt1’s expression as observed using im-
munohistochemistry showed reduced nuclear expression
(decreased to 52.74 ± 12.72% compared to donor) with
advanced heart failure (Figure 1B). This result is similarFigure 1 Sirt1 is down-regulated in cardiomyocytes from patients wit
prepared from the recipient and donor heart sample. (A) Expression of Sirt
is expressed as 1. H9c2 cells treated with Ad-Sirt1 was used as a positive co
patients were subjected to hematoxylin-eosin staining (upper) and immuno
(green), and DAPI (blue). The number of Sirt1 positive nuclei/total nuclei of
of hearts from old (15 months) and young (3 months) mice were subjected
The number of Sirt1 positive nuclei/total nuclei of young heart is expressedto those observed in changes to the aging murine hearts
(Figure 1C).
MnSOD, Trx1, and apoptotic proteins are modulated in
advanced heart failure
The expression of downstream targets of Sirt1, such as
Mn-superoxide dismutase (MnSOD) which is modulated
by Sirt1 [14], Trx1, and the molecules associated with apop-
totic signaling pathway were analyzed using immunoblot.
The expressions of beneficial molecules, such as MnSOD,
Trx1 and Bcl-xL (0.71 ± 0.02-fold, 0.61 ± 0.05-fold, and
0.53 ± 0.08-fold vs. donor, respectively) are all decreased in
advanced heart failure (Figure 2A and B). The expression of
Bax was significantly increased (1.62 ± 0.18-fold vs. donor)
in advanced heart failure (Figure 2A and B).h advanced heart failure. Atrial myocardial homogenates were
1 and tubulin was evaluated by immunoblots. The level of donor heart
ntrol. (B) Atrial myocardial sections from the recipient and donor
staining (lower) with anti-troponin C antibody (red), anti-Sirt1 antibody
donor heart is expressed as 1. (C) The ventricular myocardial sections
to immunostaining with anti-Sirt1 antibody (green) and DAPI (blue).
as 1.
Figure 2 MnSOD, Trx1, and apoptotic proteins are modulated in advanced heart failure. Atrial myocardial homogenates were prepared
from the recipient and donor heart sample. (A) Expression of MnSOD, Trx1, Bax, Bcl-xL, acetyl-p53, p53 (total) and tubulin was evaluated by
immunoblots. The level of donor heart is expressed as 1. (B) Representative immunoblots.
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increased in advanced heart failure
TUNEL staining for both recipient and donor hearts
was performed to further investigate changes associated
with aging. The number of TUNEL positive cardiomyo-
cytes in the heart failure group was increased significantly
compared with normal donor control cardiomyocytes
(Figure 3A). Due to the lower expression of Trx1 in ad-
vanced heart failure, differences in oxidative stress of the myo-
cardium were further examined. 8-hydroxydeoxyguanosine
(8-OHdG), a critical marker of oxidative damage of gen-
omic DNA and the aging process [15,16], was characterized
using immunohistochemistry. Results showed increased
oxidative stress in both nucleus and cytosol of cardiomyo-
cytes in advanced heart failure, similar to the changes
observed in aged cardiomyocytes (Figure 3B and C).
The activity of the AMPK-Nampt-Sirt1 axis is decreased in
the advanced heart failure
Since both AMPK and Nampt are the upstream mole-
cules of the functional signaling pathway of the AMPK-
Nampt-Sirt1 axis [17], we examined their expression in
advanced heart failure. Whether the axis of AMPK-
Nampt-Sirt1 was functional in the heart was determined
under the treatment of compound C, an AMPK inhibi-
tor. The expression of both Nampt and Sirt1 was de-
creased in H9c2 cells, which implied that the axis maywork in the heart (Figure 4A). The expression of both
AMPK and Nampt was also decreased (0.60 ± 0.06-fold
and 0.52 ± 0.08-fold vs. donor, respectively) in advanced
heart failure as Sirt1’s expression (Figure 4B). Further-
more, the expression of phospho-AMPK was severely
inhibited in advanced heart failure (Figure 4B). In order
to confirm these results, hearts from an aging C57/B6
mouse was examined. The expression of AMPK, Sirt1 and
MnSOD was decreased in the old mice (aged 12 months)
compared with younger mice (3 months), but the ex-
pression of Nampt was increased. The expression of phospho-
AMPK/total AMPK was also checked and showed
significantly decreased (or inhibited) in the old mice
(aged 12 months) (Figure 4C).
Translocation of Sirt1 and regulation of FoxO1 and p53 in
advanced heart failure
Due to lower expression of Sirt1 and MnSOD in heart
failure, translocation of transcriptional factor FoxO1,
which could modulate the expression of MnSOD [18],
was examined, Immunostaining revealed decreased FoxO1
in the nucleus in advanced heart failure cardiomyocytes
(Figure 5A). Furthermore, because of the increased ex-
pression of Bax, a downstream effector that is positively
regulated by p53 in heart failure [19], we examined acety-
lated p53, which was significantly increased in advanced
heart failure (Figure 5B).
Figure 3 Apoptosis and oxidative stress are aggravated in advanced heart failure. Atrial myocardial sections from the recipient and donor
patients were subjected to (A) TUNEL, troponin C and DAPI staining, the number of TUNEL-positive myocytes was expressed as a percentage of
total nuclei detected by DAPI staining. and (B) 8-OHdG immunostaining. Representative images of the staining are shown. (C) The ventricular
myocardial sections of hearts from old (15 months) and young (3 months) mice were subjected to immunostaining with 8-OHdG, and representative
images of the staining are shown.
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This is a cross-sectional study designed to investigate
the expression of Sirt1 and its associated molecules in
the left atrium from the end-stage heart failure patients,
and compared those from even younger donors. Simul-
taneously, these changes in heart failure are found to be
similar to those observed in aging mice. Both of our
study and Sakamoto et al’s, [9] showed that the expres-
sion of Sirt1 in the heart is decreased with age. The gap
in age, in spite of statistical insignificance, may have
some minor effect on the Sirt1’s expression. Hence, we
checked whether the expression of Sirt1 is affected by
aging effect in our sample (Additional file 1: Figure S1).
It showed that it could be neglected, and the observa-
tions in this study are mostly related to progressive
genetic remodeling of the failing heart.
It is widely agreed that Sirt1 plays a cardioprotective role
in many aspects. There have been various studies con-
ducted on in vivo heart models [11,20], ex vivo Langendorff
model [11,20,21], or cultured cardiomyocytes [10,12,22],
which all suggested that Sirt1 serves a protective role
against cardiovascular stresses through the regulation of
apoptosis inhibition, aging retardation, and oxidative
stress alleviation [6,8,10].We currently demonstrate that Sirt1 is down-regulated
in the myocardium in patients with advanced heart fail-
ure, The result, as was supposed, is very similar to our
previous report [11], and consistent with the report of
human samples by Pillai et al. [13]. Alcendor et al. [10],
showed that Sirt1 is up-regulated (8.8-fold of protein
expression) after 4 weeks of pressure overload in mice, a
condition used to represent the stage of heart failure,
however, they did not check the cardiac function of
these mice, nor the activity of Sirt1. Increase of Sirt1 ex-
pression in the heart was associated with cardiac hyper-
trophy [10,23], however, the constitutive high level of
Sirt1 may be harmful to the heart itself and reduce car-
diac function, proved by transgenic model [10,24]. It also
points out that the expression level of Sirt1 is important,
too much is as bad as too little. In our study, we found
that Sirt1 is obvious decreased in the heart of 12 or15
month mice, and a significant decline in left ventricular
systolic function was not noted until 18 months of age
in the C57BL/6J mice [25], the same background of
mouse as our study. Taken above findings altogether, it
might be assumed that Sirt1 may be highly up-regulated
to protect the cardiomyocytes in the early stage of heart
failure (compensated stage) associated with pressure-
Figure 4 The activity of the AMPK-Nampt-Sirt1 axis is decreased in the advanced heart failure. (A) H9c2 cells were treated with
compound C at indicated concentrations and cultured for 24 hours. Cell lysates were subjected to immunoblot analyses with anti-AMPK,
anti-Nampt, anti-Sirt1 and anti-tubulin. The results shown are one representative of four independent experiments. (B) Atrial myocardial homogenates
were prepared from the heart recipient and donor patients, respectively. Expression of phospho-AMPK(Thr172), AMPK, Nampt, and tubulin
was evaluated by immunoblots. The level of donor heart is expressed as 1. Representative immunoblots were shown. (C) Heart homogenates were
prepared from C57/B6 mice aged 1 week, 1 month, 3 months, and 12 months. Expression of phospho-AMPK(Thr172), AMPK, Nampt, Sirt1, MnSOD
and tubulin was evaluated by immunoblots, and the level of phospho-AMPK/total AMPK, Nampt, Sirt1, and MnSOD was compared between
3-month (expressed as 1) and 12-month mice.
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tion of Sirt1’s expression in dog by Alcendor et al. [12],
however, the sustained too high level of Sirt1 is not benefi-
cial, but detrimental to the cardiomyocytes through un-
clear mechanisms and the expression of Sirt1 may be
progressively decreased accompanying the injury of cardio-
myocytes in the long run (decompensated stage), and con-
tributes partly to heart failure finally. More experiments
are necessary to investigate the hypothesis. Furthermore,
the reason for the discrepancy about higher expression of
Sirt1 in old monkeys by Alcendor et al. [10] remains to be
elucidated, and whether any stress impacted on these old
monkeys or not should be explored.
We have previously reported that Sirt1 can stimulate
the expression of MnSOD in cultured cardiomyocytes, forwhich FoxO1 has been shown to play an essential role
[11], and in response to serum starvation in vitro, the dea-
cetylation of p53 by Sirt1 inhibits cardiac myocytes apop-
tosis [12]. We currently report that in advanced heart
failure, both the FoxO1 and deacetylation of p53 were
significantly reduced in the nuclei of cardiomyocytes.
These may be the mechanisms of reduced MnSOD,
Bcl-xL, and increased Bax, apoptosis, and oxidative stress
with the downregulation of Sirt1 expression.
Regardless of the stressor, downregulation of Sirt1 in
the heart was associated with loss of cardioprotection in
the literatures, such as our result that low expression of
Sirt1 in advanced heart failure may lead to additional
irreversible heart injury via downstream effectors. How-
ever, further studies are necessary to fully elucidate the
Figure 5 Sirt1 modulates p53 and nuclear localization of FoxO1 in advanced heart failure. (A) Atrial myocardial sections from the heart
recipient and donor patients, respectively were subjected to immunostaining with anti-FoxO1 antibody (green), anti-troponin C antibody (red),
and DAPI (blue). The number of FoxO1-positive nuclei was expressed as a percentage of total nuclei. (B) Atrial myocardial sections from the heart
recipient and donor patients were subjected to immunostaining with anti-acetyl p53 antibody (red) and DAPI (blue). The number of acetyl-p53
positive nuclei was expressed as a percentage of total nuclei detected by DAPI staining.
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relationship between Sirt1 and mechanical or neurohor-
monal stimulus of the failing heart before we target it.
Sirtuin activity is regulated by NAD+ biosynthetic
pathways, in which Nampt plays a critical role as a regu-
lator for NAD+ synthesis in cardiomyocytes [26]. Fulco
et al. showed that the axis of AMPK-Nampt-Sirt1 was a
functional pathway to sense and react to nutrient avail-
ability in skeletal muscle cells [17]. We also examine it
in our samples and find the expression of Nampt is
inconsistent in aged murine hearts and advanced heart
failure. In aged heart, the expression of Nampt is in-
creased, which may be secondary to compensate for the
decrease of Sirt1. Moreover, in the mouse sample, the
expression of phospho-AMPK and MnSOD is not syn-
chronous to that of Sirt1 in the early age. The activation
of phospho-AMPK in the early neonatal life may be
likely associated with starvation (fasting) after birth, andit may imply that the regulation of these molecules is
more complicated than our mention.
Our result suggests that the AMPK-Nampt-Sirt1 path-
way may be disordered in heart failure and the mechan-
ism of aging and heart failure is similar but not exactly
the same. It also implicates that multiple molecular path-
ways involved in determining aging process. Recently, Ma
et al. [27] also showed that ischemic AMPK activation
was impaired in aged murine hearts, and Reznick et al.
[28] disclosed that aging-associated reductions in AMPK
activity may be an important contributing factor in re-
duced mitochondrial function and dysregulated intra-
cellular lipid metabolism. We also report similar results of
AMPK change in aged murine hearts. Per results provided
by Fulco et al. glucose restriction (or nutrient short-
age) functions to keep skeletal myoblasts from differ-
entiation and hold them in the younger (undifferentiated)
stage through activated AMPK. Although the exact
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ence various cell signaling/modulators of lifespan re-
main a largely unresolved issue. However, the above
findings showed that the AMPK and/or activated AMPK,
and the modulated Sirt1, may be regarded as important
regulators or markers of aging, even the differentiation of
cardiomyocytes. Upregulation of the functioning pathway
can be an alternative method apart from increasing Sirt1’s
activity or expression, as a cardioprotective intervention.
The metabolism of nutrition in the myocardium will
change substantially during advanced heart failure, how-
ever, further experiments are necessary to elucidate the
role of Sirt1 on the metabolic remodeling of the failing
heart.Clinical relevance
Downregulation of Sirt1 may have important meaning
in the advanced heart failure, though cause and effect
relationship is not yet established in our observation.
Sirt1 agonists, such as Resveratrol, has been shown to pro-
tect the heart from ischemia/reperfusion [29]. Recently,
Telmisartan, an angiotensin receptor blocker used in the
management of hypertension or heart failure, was found
to activate the AMPK-Sirt1 pathway in skeletal muscle,
and ameliorate insulin sensitivity of obese db/db mice
[30]. These Sirt1 agonists may prevent changes associated
with cardiac aging, and targeting Sirt1 may become a
promising modality to protect the heart from aging or
heart failure.Limitation
There are several limitations in the study. One is be-
cause of impossibility to obtain the ventricular sample
from the donor heart, we only used left atrium samples
instead of left ventricle. Even though, we can not get the
similar region from left atrium between donor and re-
cipient heart while heart transplantation. Another is that
the cause of heart failure is dilated cardiomyopathy in
our study, younger than congestive heart failure due to
ischemic heart disease, hypertension, or valvular heart
disease. The observations may not be applied completely
to other causes of congestive heart failure. Further inves-
tigations may be necessary to explore the difference.Conclusions
In conclusion, in advanced heart failure, the changes
associated with aging may be accelerated and the cardio-
protective effect of Sirt1 is reduced due to the lower
expression level and changes to downstream effector
molecules. In addition, the reduced overall expression of
AMPK-Nampt-Sirt1 may partly explain the molecular
basis of this mechanism.Additional file
Additional file 1: Figure S1. The regression analysis of relative
expression of Sirt1 and age of patient in our sample. The coefficient of
determination (R-Square) of both donor and recipient sample is 0.
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